Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can Weight-Loss surgery rewire fat hormones for better metabolism?

NCT ID NCT07806448

Knowledge-focused Sponsor: General Committee of Teaching Hospitals and Institutes, Egypt Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 08, 2026 · Last updated Sep 09, 2026 · Updated 1 time

Summary

This study follows 160 people for 12 months after laparoscopic sleeve gastrectomy to measure changes in two hormones made by fat tissue: asprosin and neuregulin 4. Asprosin rises with obesity and insulin resistance, while neuregulin 4 falls, and researchers want to see if their shifts after surgery relate to metabolic improvements independent of weight loss. Participants include people with a BMI of 35 or higher, or 30 with metabolic disease, plus a non-obese reference group. A nested sub-study uses a mixed meal to test how these hormones respond to eating.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
laparoscopic sleeve gastrectomy
What this could lead to
If it works, this could clarify how weight-loss surgery improves metabolism, possibly pointing to new drug targets for obesity and insulin resistance.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply beyond the specific group studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

160 people

The number who actually took part.

Started

Jul 2025

Finished

Aug 2026

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Eligibility for surgery follows the 2022 American Society for Metabolic and Bariatric Surgery and International Federation for the Surgery of Obesity and Metabolic Disorders indications, which supersede the 1991 National Institutes of Health thresholds. Metabolic and bariatric surgery is indicated at a body mass index of at least 35 kg/m² regardless of the presence, absence or severity of obesity-related comorbidities, and should be considered at 30-34.9 kg/m² in the presence of metabolic disease. Ethnicity-adjusted thresholds are applied where relevant. Baseline phenotyping additionally records the components of the 2025 framework for clinical versus preclinical obesity for descriptive purposes; eligibility is determined by the 2022 indications.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * body mass index of at least 35 kg/m² regardless of the presence * absence or severity of obesity-related comorbidities * should be considered at 30-34.9 kg/m² in the presence of metabolic disease Exclusion Criteria: * revisional or emergency surgery * type 1 diabetes or insulin-treated type 2 diabetes * use within three months of a GLP-1 receptor agonist * dual GIP/GLP-1 receptor agonist * SGLT2 inhibitor or thiazolidinedione * systemic corticosteroid or immunosuppressive therapy * chronic liver disease of non-metabolic aetiology or cirrhosis * alcohol intake above 20 g/day in women or 30 g/day in men * estimated glomerular filtration rate below 60 mL/min/1.73 m² * FBN1-related connective tissue disorder * active or recent malignancy * untreated thyroid * adrenal or gonadal disorder * pregnancy or lactation * any device precluding bioelectrical impedance analysis * high-sensitivity C-reactive protein above 10 mg/L at baseline

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bariatric sleeve gastrectomy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Arachnodactyly Insulin Resistance obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bariatric sleeve gastrectomy

Contacts and locations

Locations

  • The surgical department of Medical Research Institute Hospital, Alexandria University

    Alexandria, 21531, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.